What is Redx Pharma?
Founded in 2010 and based in the United Kingdom, Redx Pharma is a biopharmaceutical company dedicated to advancing drug discovery and development. The company's core strategy involves enhancing the characteristics of established drug classes to create novel therapeutics for critical areas such as oncology, infectious diseases, and autoimmune disorders. Redx Pharma's commitment to innovation positions it as a key player in the pharmaceutical landscape, aiming to address unmet medical needs through scientific rigor and strategic development.
How much funding has Redx Pharma raised?
Redx Pharma has raised a total of $15.2M across 2 funding rounds:
Private Equity
$14.2M
Grant
$1M
Private Equity (2016): $14.2M, investors not publicly disclosed
Grant (2017): $1M led by Carb-X
Key Investors in Redx Pharma
Carb-X
CARB-X is a global accelerator focused on combating dangerous drug-resistant bacteria by supporting the development of new antibiotics and other life-saving products. They invest in early-stage antibiotics, preventatives, and diagnostics to address the urgent challenge of antibiotic resistance.
What's next for Redx Pharma?
The recent major strategic investment in Redx Pharma signals a pivotal phase for the company, likely enabling accelerated progression of its drug pipeline through preclinical and clinical trials. This infusion of capital is expected to bolster research and development efforts, potentially leading to significant advancements in treatments for cancer, infection, and autoimmune diseases. The company's focus on improving existing drug classes suggests a pragmatic approach to drug development, aiming for faster market entry and enhanced therapeutic profiles. Redx Pharma is poised to leverage this backing to further its mission of creating impactful new medicines.
See full Redx Pharma company page
